Financhill
Sell
45

WST Quote, Financials, Valuation and Earnings

Last price:
$329.19
Seasonality move :
6.94%
Day range:
$326.33 - $335.53
52-week range:
$265.00 - $413.70
Dividend yield:
0.24%
P/E ratio:
49.17x
P/S ratio:
8.53x
P/B ratio:
8.72x
Volume:
2.4M
Avg. volume:
566.7K
1-year change:
-5.18%
Market cap:
$24B
Revenue:
$2.9B
EPS (TTM):
$6.74

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
WST
West Pharmaceutical Services
$709.6M $1.49 1.63% -5.76% $371.01
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
MMSI
Merit Medical Systems
$334.6M $0.80 7.12% 71.67% $113.20
RGEN
Repligen
$153.3M $0.33 0.61% 10.79% $191.46
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
WST
West Pharmaceutical Services
$331.40 $371.01 $24B 49.17x $0.21 0.24% 8.53x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
MMSI
Merit Medical Systems
$98.18 $113.20 $5.7B 47.89x $0.00 0% 4.35x
RGEN
Repligen
$144.47 $191.46 $8.1B 628.56x $0.00 0% 12.82x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
WST
West Pharmaceutical Services
6.86% 0.654 0.93% 1.97x
CATX
Perspective Therapeutics
-- -5.312 -- --
MMSI
Merit Medical Systems
36.19% 0.720 13.03% 3.66x
RGEN
Repligen
20.55% 1.044 6.26% 8.43x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
WST
West Pharmaceutical Services
$264.7M $165.7M 16.89% 18.16% 22.12% $98.8M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
MMSI
Merit Medical Systems
$157.5M $37.4M 6.16% 9.56% 12.99% $37.4M
RGEN
Repligen
$77.5M -$7.8M -0.32% -0.41% 2.57% $42.2M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

West Pharmaceutical Services vs. Competitors

  • Which has Higher Returns WST or CATX?

    Perspective Therapeutics has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of --. West Pharmaceutical Services's return on equity of 18.16% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About WST or CATX?

    West Pharmaceutical Services has a consensus price target of $371.01, signalling upside risk potential of 11.95%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than West Pharmaceutical Services, analysts believe Perspective Therapeutics is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    6 3 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is WST or CATX More Risky?

    West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock WST or CATX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or CATX?

    West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Perspective Therapeutics quarterly revenues of --. West Pharmaceutical Services's net income of $136M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.17x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.53x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns WST or MMSI?

    Merit Medical Systems has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of 8.37%. West Pharmaceutical Services's return on equity of 18.16% beat Merit Medical Systems's return on equity of 9.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
    MMSI
    Merit Medical Systems
    46.36% $0.48 $2.1B
  • What do Analysts Say About WST or MMSI?

    West Pharmaceutical Services has a consensus price target of $371.01, signalling upside risk potential of 11.95%. On the other hand Merit Medical Systems has an analysts' consensus of $113.20 which suggests that it could grow by 15.3%. Given that Merit Medical Systems has higher upside potential than West Pharmaceutical Services, analysts believe Merit Medical Systems is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    6 3 0
    MMSI
    Merit Medical Systems
    5 1 0
  • Is WST or MMSI More Risky?

    West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.557%.

  • Which is a Better Dividend Stock WST or MMSI?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or MMSI?

    West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Merit Medical Systems quarterly revenues of $339.8M. West Pharmaceutical Services's net income of $136M is higher than Merit Medical Systems's net income of $28.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.17x while Merit Medical Systems's PE ratio is 47.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.53x versus 4.35x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
    MMSI
    Merit Medical Systems
    4.35x 47.89x $339.8M $28.4M
  • Which has Higher Returns WST or RGEN?

    Repligen has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -0.42%. West Pharmaceutical Services's return on equity of 18.16% beat Repligen's return on equity of -0.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
    RGEN
    Repligen
    50.03% -$0.01 $2.5B
  • What do Analysts Say About WST or RGEN?

    West Pharmaceutical Services has a consensus price target of $371.01, signalling upside risk potential of 11.95%. On the other hand Repligen has an analysts' consensus of $191.46 which suggests that it could grow by 32.53%. Given that Repligen has higher upside potential than West Pharmaceutical Services, analysts believe Repligen is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    6 3 0
    RGEN
    Repligen
    9 5 0
  • Is WST or RGEN More Risky?

    West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Repligen has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.502%.

  • Which is a Better Dividend Stock WST or RGEN?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or RGEN?

    West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Repligen quarterly revenues of $154.9M. West Pharmaceutical Services's net income of $136M is higher than Repligen's net income of -$654K. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.17x while Repligen's PE ratio is 628.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.53x versus 12.82x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
    RGEN
    Repligen
    12.82x 628.56x $154.9M -$654K
  • Which has Higher Returns WST or VTAK?

    Catheter Precision has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -4291.67%. West Pharmaceutical Services's return on equity of 18.16% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About WST or VTAK?

    West Pharmaceutical Services has a consensus price target of $371.01, signalling upside risk potential of 11.95%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than West Pharmaceutical Services, analysts believe Catheter Precision is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    6 3 0
    VTAK
    Catheter Precision
    0 0 0
  • Is WST or VTAK More Risky?

    West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock WST or VTAK?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or VTAK?

    West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Catheter Precision quarterly revenues of $96K. West Pharmaceutical Services's net income of $136M is higher than Catheter Precision's net income of -$4.1M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.17x while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.53x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns WST or XTNT?

    Xtant Medical Holdings has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -17.98%. West Pharmaceutical Services's return on equity of 18.16% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    35.44% $1.85 $3B
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About WST or XTNT?

    West Pharmaceutical Services has a consensus price target of $371.01, signalling upside risk potential of 11.95%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than West Pharmaceutical Services, analysts believe Xtant Medical Holdings is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    6 3 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is WST or XTNT More Risky?

    West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock WST or XTNT?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or XTNT?

    West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. West Pharmaceutical Services's net income of $136M is higher than Xtant Medical Holdings's net income of -$5M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.17x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.53x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    8.53x 49.17x $746.9M $136M
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 3.65% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 4.9% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock